|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng R, Zeng H, Zhang S, Chen T and Chen
W: National estimates of cancer prevalence in China, 2011. Cancer
Lett. 370:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anzick SL, Kononen J, Walker RL, Azorsa
DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM and
Meltzer PS: AIB1, a steroid receptor coactivator amplified in
breast and ovarian cancer. Science. 277:965–968. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou HJ, Yan J, Luo W, Ayala G, Lin SH,
Erdem H, Ittmann M, Tsai SY and Tsai MJ: SRC-3 is required for
prostate cancer cell proliferation and survival. Cancer Res.
65:7976–7983. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan J, Tsai SY and Tsai MJ: SRC-3/AIB1:
Transcriptional coactivator in oncogenesis. Acta Pharmacol Sin.
27:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liao L, Kuang SQ, Yuan Y, Gonzalez SM,
O'Malley BW and Xu J: Molecular structure and biological function
of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J
Steroid Biochem Mol Biol. 83:3–14. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cai D, Shames DS, Raso MG, Xie Y, Kim YH,
Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, et al: Steroid
receptor coactivator-3 expression in lung cancer and its role in
the regulation of cancer cell survival and proliferation. Cancer
Res. 70:6477–6485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Long W, Foulds CE, Qin J, Liu J, Ding C,
Lonard DM, Solis LM, Wistuba II, Qin J, Tsai SY, et al: ERK3
signals through SRC-3 coactivator to promote human lung cancer cell
invasion. J Clin Invest. 122:1869–1880. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao W, Chang C, Cui Y, Zhao X, Yang J,
Shen L, Zhou J, Hou Z, Zhang Z, Ye C, et al: Steroid receptor
coactivator-3 regulates glucose metabolism in bladder cancer cells
through coactivation of hypoxia inducible factor 1α. J Biol Chem.
289:11219–11229. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo JH, Xie D, Liu MZ, Chen W, Liu YD, Wu
GQ, Kung HF, Zeng YX and Guan XY: Protein expression and
amplification of AIB1 in human urothelial carcinoma of the bladder
and overexpression of AIB1 is a new independent prognostic marker
of patient survival. Int J Cancer. 122:2554–2561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan J, Erdem H, Li R, Cai Y, Ayala G,
Ittmann M, Yu-Lee LY, Tsai SY and Tsai MJ: Steroid receptor
coactivator-3/AIB1 promotes cell migration and invasiveness through
focal adhesion turnover and matrix metalloproteinase expression.
Cancer Res. 68:5460–5468. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Louie MC, Zou JX, Rabinovich A and Chen
HW: ACTR/AIB1 functions as an E2F1 coactivator to promote breast
cancer cell proliferation and antiestrogen resistance. Mol Cell
Biol. 24:5157–5171. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tong ZT, Wei JH, Zhang JX, Liang CZ, Liao
B, Lu J, Fan S, Chen ZH, Zhang F, Ma HH, et al: AIB1 predicts
bladder cancer outcome and promotes bladder cancer cell
proliferation through AKT and E2F1. Br J Cancer. 108:1470–1479.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Watanabe K, Watanabe HY, Goto Y, Yamamoto
N and Yoshizaki M: Studies on the active principles of magnolia
bark. Centrally acting muscle relaxant activity of magnolol and
hōnokiol. Jpn J Pharmacol. 25:605–607. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arora S, Singh S, Piazza GA, Contreras CM,
Panyam J and Singh AP: Honokiol: A novel natural agent for cancer
prevention and therapy. Curr Mol Med. 12:1244–1252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Esumi T, Makado G, Zhai H, Shimizu Y,
Mitsumoto Y and Fukuyama Y: Efficient synthesis and
structure-activity relationship of honokiol, a neurotrophic
biphenyl-type neolignan. Bioorg Med Chem Lett. 14:2621–2625. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Q, Zhao W, Ye C, Zhuang J, Chang C,
Li Y, Huang X, Shen L, Li Y, Cui Y, et al: Honokiol inhibits
bladder tumor growth by suppressing EZH2/miR-143 axis. Oncotarget.
6:37335–37348. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cheng S, Castillo V, Eliaz I and Sliva D:
Honokiol suppresses metastasis of renal cell carcinoma by targeting
KISS1/KISS1R signaling. Int J Oncol. 46:2293–2298. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jeong JJ, Lee JH, Chang KC and Kim HJ:
Honokiol exerts an anticancer effect in T98G human glioblastoma
cells through the induction of apoptosis and the regulation of
adhesion molecules. Int J Oncol. 41:1358–1364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khan MA, Tania M, Wei C, Mei Z, Fu S,
Cheng J, Xu J and Fu J: Thymoquinone inhibits cancer metastasis by
downregulating TWIST1 expression to reduce epithelial to
mesenchymal transition. Oncotarget. 6:19580–19591. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) methods. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gheldof A and Berx G: Cadherins and
epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci.
116:317–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tania M, Khan MA and Fu J: Epithelial to
mesenchymal transition inducing transcription factors and
metastatic cancer. Tumour Biol. 35:7335–7342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McConkey DJ, Choi W, Marquis L, Martin F,
Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role
of epithelial-to-mesenchymal transition (EMT) in drug sensitivity
and metastasis in bladder cancer. Cancer Metastasis Rev.
28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jäger T, Becker M, Eisenhardt A, Tilki D,
Tötsch M, Schmid KW, Romics I, Rübben H, Ergün S and Szarvas T: The
prognostic value of cadherin switch in bladder cancer. Oncol Rep.
23:1125–1132. 2010.PubMed/NCBI
|
|
27
|
Guo S, Xu J, Xue R, Liu Y and Yu H:
Overexpression of AIB1 correlates inversely with E-cadherin
expression in pancreatic adenocarcinoma and may promote lymph node
metastasis. Int J Clin Oncol. 19:319–324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang M, Zhao F, Li S, Chang AK, Jia Z,
Chen Y, Xu F, Pan H and Wu H: AIB1 cooperates with ERα to promote
epithelial mesenchymal transition in breast cancer through SNAI1
activation. PLoS One. 8:e655562013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qin L, Liu Z, Chen H and Xu J: The steroid
receptor coactivator-1 regulates twist expression and promotes
breast cancer metastasis. Cancer Res. 69:3819–3827. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto
GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA and Yeh S:
Estrogen receptor alpha prevents bladder cancer via INPP4B
inhibited akt pathway in vitro and in vivo. Oncotarget.
5:7917–7935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill
TG and O'Malley BW: Small molecule inhibition of the steroid
receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol.
25:2041–2053. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill
TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, et al: Bufalin is a
potent small-molecule inhibitor of the steroid receptor
coactivators SRC-3 and SRC-1. Cancer Res. 74:1506–1517. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yan F, Yu Y, Chow DC, Palzkill T, Madoux
F, Hodder P, Chase P, Griffin PR, O'Malley BW and Lonard DM:
Identification of verrucarin a as a potent and selective steroid
receptor coactivator-3 small molecule inhibitor. PLoS One.
9:e952432014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Avtanski DB, Nagalingam A, Bonner MY,
Arbiser JL, Saxena NK and Sharma D: Honokiol inhibits
epithelial-mesenchymal transition in breast cancer cells by
targeting signal transducer and activator of transcription
3/Zeb1/E-cadherin axis. Mol Oncol. 8:565–580. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leeman-Neill RJ, Cai Q, Joyce SC, Thomas
SM, Bhola NE, Neill DB, Arbiser JL and Grandis JR: Honokiol
inhibits epidermal growth factor receptor signaling and enhances
the antitumor effects of epidermal growth factor receptor
inhibitors. Clin Cancer Res. 16:2571–2579. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ahn KS, Sethi G, Shishodia S, Sung B,
Arbiser JL and Aggarwal BB: Honokiol potentiates apoptosis,
suppresses osteoclastogenesis, and inhibits invasion through
modulation of nuclear factor-kappaB activation pathway. Mol Cancer
Res. 4:621–633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu SH, Lee WJ, Lai DW, Wu SM, Liu CY,
Tien HR, Chiu CS, Peng YC, Jan YJ, Chao TH, et al: Honokiol confers
immunogenicity by dictating calreticulin exposure, activating ER
stress and inhibiting epithelial-to-mesenchymal transition. Mol
Oncol. 9:834–849. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Joo YN, Eun SY, Park SW, Lee JH, Chang KC
and Kim HJ: Honokiol inhibits U87MG human glioblastoma cell
invasion through endothelial cells by regulating membrane
permeability and the epithelial-mesenchymal transition. Int J
Oncol. 44:187–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
